An epistolary account of cabozantinib’s significance in the combat against renal cell, hepatocellular, and thyroid carcinoma from the perspective of a cancer combatant-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

An epistolary account of cabozantinib’s significance in the combat against renal cell, hepatocellular, and thyroid carcinoma from the perspective of a cancer combatant

Published:2023 Issue:2 Volume:6 Page:343-344
ISSN:2590-3233
Container-title:Cancer Research, Statistics, and Treatment
language:en
Short-container-title:

Author:

Bhattacharya Sankha¹

Affiliation:

1. School of Pharmacy and Technology Management, SVKM’S NMIMS Deemed-to-be University, Shirpur, Maharashtra, India

Publisher

Medknow

Subject

Cancer Research,Oncology (nursing),Drug Guides,Oncology

Reference12 articles.

1. Cabozantinib:A narrative drug review;Srigadha;Cancer Res Stat Treat,2023

2. Management of adverse events associated with cabozantinib treatment in patients with advanced hepatocellular carcinoma;Schwartz;Target Oncol,2020

3. Cabozantinib for the treatment of solid tumors:A systematic review;Maroto;Ther Adv Med Oncol,2022

4. Cabozantinib in progressive medullary thyroid cancer;Elisei;J Clin Oncol,2013

5. Neoadjuvant cabozantinib in metastatic and locally advanced renal cell carcinoma;Roy;Cancer Res Stat Treat,2021

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Authors’ reply to Bhattacharya;Cancer Research, Statistics, and Treatment;2023

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP